Intermittent epoprostenol (prostacyclin) infusion in patients with Raynaud's syndrome. A double-blind controlled trial.

Abstract

Two groups of outpatients (7 in each group) with Raynaud's syndrome, matched for severity of illness, were randomly allocated to receive at weekly intervals for three weeks either a 5 h intravenous infusion of buffer or epoprostenol (prostacyclin, PGI2) in buffer (7.5 ng/kg/min after the first hour). PGI2 reduced the frequency and duration of ischaemic attacks (both p less than 0.01). Hand temperature measurements with a thermocouple were significantly improved at 1 week; 6 weeks after the last infusion hand temperatures had returned to baseline. There was a corresponding loss of clinical response 8-10 weeks after the last infusion.

Statistics

050100150'87'90'93'96'99'02'05'08'11'14'17
Citations per Year

596 Citations

Semantic Scholar estimates that this publication has 596 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Belch1983IntermittentE, title={Intermittent epoprostenol (prostacyclin) infusion in patients with Raynaud's syndrome. A double-blind controlled trial.}, author={Jill J. F. Belch and Piers Newman and Jason Drury and Fiona Mckenzie and Hilary A Capell and P J Leiberman and Carol Forbes and Cameron M Prentice}, journal={Lancet}, year={1983}, volume={1 8320}, pages={313-5} }